AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon-Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations
Shun Lu, Xiaorong Dong, Hong Jian, Jianhua Chen, Gongyan Chen, Yuping Sun, Yinghua Ji, Ziping Wang, Jianhua Shi, Junguo Lu, Shaoshui Chen, Dongqing Lv, Guojun Zhang, Chunling Liu, Juan Li, Xinmin Yu, Zhong Lin, Zhuang Yu, Zhehai Wang, Jiuwei Cui, Xingxiang Xu, Jian Fang, Jifeng Feng, Zhi Xu, Rui Ma, Jie Hu, Nong Yang, Xiangdong Zhou, Xiaohong Wu, Chengping Hu, Zhihong Zhang, You Lu, Yanping Hu, Liyan Jiang, Qiming Wang, Renhua Guo, Jianying Zhou, Baolan Li, Chunhong Hu, Wancheng Tong, Helong Zhang, Lin Ma, Yuan Chen, Zhijun Jie, Yu Yao, Longzhen Zhang, Weng Jie, Weidong Li, Jianping Xiong, Xianwei Ye, Jianchun Duan, Haihua Yang, Meili Sun, Changan Sun, Hongying Wei, Chuan Li, Siraj M Ali, Vincent A Miller, Qiong Wu, Shun Lu, Xiaorong Dong, Hong Jian, Jianhua Chen, Gongyan Chen, Yuping Sun, Yinghua Ji, Ziping Wang, Jianhua Shi, Junguo Lu, Shaoshui Chen, Dongqing Lv, Guojun Zhang, Chunling Liu, Juan Li, Xinmin Yu, Zhong Lin, Zhuang Yu, Zhehai Wang, Jiuwei Cui, Xingxiang Xu, Jian Fang, Jifeng Feng, Zhi Xu, Rui Ma, Jie Hu, Nong Yang, Xiangdong Zhou, Xiaohong Wu, Chengping Hu, Zhihong Zhang, You Lu, Yanping Hu, Liyan Jiang, Qiming Wang, Renhua Guo, Jianying Zhou, Baolan Li, Chunhong Hu, Wancheng Tong, Helong Zhang, Lin Ma, Yuan Chen, Zhijun Jie, Yu Yao, Longzhen Zhang, Weng Jie, Weidong Li, Jianping Xiong, Xianwei Ye, Jianchun Duan, Haihua Yang, Meili Sun, Changan Sun, Hongying Wei, Chuan Li, Siraj M Ali, Vincent A Miller, Qiong Wu
Abstract
Purpose: Aumolertinib (formerly almonertinib; HS-10296) is a novel third-generation epidermal growth factor receptor tyrosine kinase inhibitor approved in China. This double-blind phase III trial evaluated the efficacy and safety of aumolertinib compared with gefitinib as a first-line treatment for locally advanced or metastatic EGFR-mutated non-small-cell lung cancer (NSCLC; ClinicalTrials.gov identifier: NCT03849768).
Methods: Patients at 53 sites in China were randomly assigned 1:1 to receive either aumolertinib (110 mg) or gefitinib (250 mg) once daily. The primary end point was progression-free survival (PFS) per investigator assessment.
Results: A total of 429 patients who were naïve to treatment for locally advanced or metastatic NSCLC were enrolled. PFS was significantly longer with aumolertinib compared with gefitinib (hazard ratio, 0.46; 95% CI, 0.36 to 0.60; P < .0001). The median PFS with aumolertinib was 19.3 months (95% CI, 17.8 to 20.8) versus 9.9 months with gefitinib (95% CI, 8.3 to 12.6). Objective response rate and disease control rate were similar in the aumolertinib and gefitinib groups (objective response rate, 73.8% and 72.1%, respectively; disease control rate, 93.0% and 96.7%, respectively). The median duration of response was 18.1 months (95% CI, 15.2 to not applicable) with aumolertinib versus 8.3 months (95% CI, 6.9 to 11.1) with gefitinib. Adverse events of grade ≥ 3 severity (any cause) were observed in 36.4% and 35.8% of patients in the aumolertinib and gefitinib groups, respectively. Rash and diarrhea (any grade) were observed in 23.4% and 16.4% of patients who received aumolertinib compared with 41.4% and 35.8% of those who received gefitinib, respectively.
Conclusion: Aumolertinib is a well-tolerated third-generation epidermal growth factor receptor tyrosine kinase inhibitor that could serve as a treatment option for EGFR-mutant NSCLC in the first-line setting.
Conflict of interest statement
Shun Lu
Consulting or Advisory Role: AstraZeneca, Pfizer, Boehringer Ingelheim, Hutchison MediPharma, Simcere Pharmaceutical Group, Zai Lab, GenomiCare, Yuhan, Prime Oncology, Roche
Speakers' Bureau: AstraZeneca, Roche, Hansoh Pharma, Hengrui Therapeutics
Research Funding: AstraZeneca (Inst), Hutchison MediPharma (Inst), BMS (Inst), Hengrui Therapeutics (Inst), BeiGene (Inst), Roche (Inst)
Xiaorong Dong
Consulting or Advisory Role: Hansoh Pharma
Research Funding: Hansoh Pharma (Inst)
Yuping Sun
Honoraria: Roche, Pfizer, AstraZeneca
Consulting or Advisory Role: AstraZeneca, Roche
Research Funding: Roche, Pfizer
Yinghua Ji
Research Funding: AoSaikang, CSPC Pharma, Hualan Bio (Inst)
Jianhua Shi
Honoraria: Roche, BeiGene
Consulting or Advisory Role: Hansoh Pharma
Research Funding: Hansoh Pharma (Inst)
Junguo Lu
Research Funding: Hansoh (Inst), Akesobio (Inst), Shanghai Henlius Biotech (Inst)
Shaoshui Chen
Consulting or Advisory Role: Hansoh Pharma
Research Funding: Hansoh Pharma (Inst)
Xinmin Yu
Research Funding: BeiGene, Innovent Biologics, BMS, MSD, Hansoh
Zhehai Wang
Consulting or Advisory Role: Hansoh Pharma
Research Funding: Hansoh Pharma (Inst)
Xingxiang Xu
Consulting or Advisory Role: Hansoh Pharma
Research Funding: Hansoh Pharma (Inst)
Jian Fang
Consulting or Advisory Role: Hansoh Pharma
Research Funding: Hansoh Pharma (Inst)
Yanping Hu
Consulting or Advisory Role: Hansoh Pharma
Research Funding: Hansoh Pharma (Inst)
Nong Yang
Consulting or Advisory Role: Hansoh Pharmaceutical Group Co, Ltd
Research Funding: Hansoh Pharmaceutical Group Co, Ltd
Xiangdong Zhou
Research Funding: MSD, AZ, Hansoh, Hengrui, Sanofi, J&J, BMS, BeiGene, Pfizer, GSK, Novartis, Chiesi (Inst)
You Lu
Honoraria: Roche/Genentech, AstraZeneca, Pfizer, Bristol Myers Squibb, Merck Sharp & Dohme, BeiGene
Consulting or Advisory Role: Roche/Genentech, AstraZeneca, Pfizer, Bristol Myers Squibb, Merck Sharp & Dohme, BeiGene
Qiming Wang
Consulting or Advisory Role: Hansoh Pharma
Research Funding: Hansoh Pharma (Inst)
Jianying Zhou
Consulting or Advisory Role: Hansoh Pharma
Research Funding: Hansoh Pharma (Inst)
Yuan Chen
Consulting or Advisory Role: Hansoh Pharma
Research Funding: Hansoh Pharma (Inst)
Haihua Yang
Consulting or Advisory Role: Hansoh Pharma
Research Funding: Hansoh Pharma (Inst)
Changan Sun
Employment: Jiangsu Hansoh Pharmaceutical Group Co, Ltd
Leadership: Jiangsu Hansoh Pharmaceutical Group Co, Ltd
Hongying Wei
Employment: Hansoh Pharma
Chuan Li
Employment: Hansoh Pharma
Siraj M. Ali
Employment: EQRX, EQRX
Leadership: Incysus, Elevation Oncology, Pillar Biosciences, Droplet Biosciences
Stock and Other Ownership Interests: Exelixis, Merus NV, Pfizer, Pfizer
Consulting or Advisory Role: Azitra, Princeptx, Archer
Patents, Royalties, Other Intellectual Property: patents via Foundation Medicine, patents via Seres Health on microbiome stuff in non-neoplastic disease
Vincent A. Miller
Employment: Foundation Medicine, EQRX
Leadership: Revolution Medicines
Stock and Other Ownership Interests: Foundation Medicine, Mirati Therapeutics, Revolution Medicines, EQRX
Patents, Royalties, Other Intellectual Property: Received periodic royalties related to T790M patent awarded to the Memorial Sloan Kettering Cancer Center
Qiong Wu
Employment: Hansoh Pharma
No other potential conflicts of interest were reported.
Figures
References
- Mok TS, Wu YL, Ahn MJ, et al. : Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med 376:629-640, 2017
- Goss G, Tsai CM, Shepherd FA, et al. : Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): A multicentre, open-label, single-arm, phase 2 study. Lancet Oncol 17:1643-1652, 2016
- Soria JC, Ohe Y, Vansteenkiste J, et al. : Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med 378:113-125, 2018
- Ramalingam SS, Vansteenkiste J, Planchard D, et al. : Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med 382:41-50, 2020
- Bao R, Zhang F, Tong Z, et al. : Discovery of a third-generation EGFR inhibitor, which is highly selective and potent against both resistant and activating EGFR mutations for NSCLC therapy. Cancer Res 76, 2016. (suppl; abstr 3036)
- Lu S, Wang Q, Zhang G, et al. : Efficacy of aumolertinib (HS-10296) in patients with advanced EGFR T790M+ NSCLC: Updated Post-National Medical Products Administration Approval results from the APOLLO registrational trial. J Thorac Oncol 17:411-422, 2022
- Yang JCH, Camidge DR, Yang CT, et al. : Safety, efficacy, and pharmacokinetics of almonertinib (HS-10296) in pretreated patients with EGFR-mutated advanced NSCLC: A multicenter, open-label, phase 1 trial. J Thorac Oncol 15:1907-1918, 2020
- Lin DY, Wei LJ, Ying Z: Checking the Cox model with cumulative sums of martingale-based residuals. Biometrika 80:557-572, 1993
- Nagasaka M, Zhu VW, Lim SM, et al. : Beyond osimertinib: The development of third-generation EGFR tyrosine kinase inhibitors for advanced EGFR+ NSCLC. J Thorac Oncol 16:740-763, 2021
- Wu YL, Tsuboi M, He J, et al. : Osimertinib in resected EGFR-mutated non-small-cell lung cancer. N Engl J Med 383:1711-1723, 2020
- Wu YL, Planchard D, Lu S, et al. : Pan-Asian adapted clinical practice guidelines for the management of patients with metastatic non-small-cell lung cancer: A CSCO-ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS. Ann Oncol 30:171-210, 2019
Source: PubMed